Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an announcement.
Neuren Pharmaceuticals has called its 2026 Annual Shareholders’ Meeting for 27 May in Melbourne, offering a hybrid format that allows investors to attend in person at the RACV City Club or participate online via a live webcast. Shareholders will be able to view the chair’s address and CEO presentation, ask questions, and vote in real time or by lodging proxies in advance.
The agenda includes receiving the company’s annual report and voting on the re-election of director Joe Basile, with all voting to be conducted by poll rather than a show of hands. Neuren is also encouraging investors to opt in for electronic communications, reflecting an ongoing shift toward digital engagement and broader remote participation in corporate governance.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$19.10 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a biopharmaceutical company incorporated in New Zealand and based in Hawthorn East, Victoria, Australia. The company operates in the pharmaceutical and biotechnology industry, focusing on the development and commercialisation of therapies for neurological and other central nervous system disorders, targeting both domestic and international healthcare markets.
Average Trading Volume: 540,264
Technical Sentiment Signal: Sell
Current Market Cap: A$1.57B
See more insights into NEU stock on TipRanks’ Stock Analysis page.